Related Experiment Video
Updated: Aug 12, 2026
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update
1Department of Intensive Care, Erasme University Hospital, Université libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium;
Abstract:
Pseudomonas aeruginosa is one of the most common causes of nosocomial infection in intensive care unit patients and is independently associated with worse outcomes. Resistance of P. aeruginosa to antimicrobial agents is increasingly common and treatment of these infections is a growing challenge for intensivists. The development of methods to prevent infection, such as vaccines, is thus of considerable interest. Three agents currently show promise in this population of patients and are undergoing clinical evaluation; however, further vaccine targets are being discovered and more potential agents will likely be developed in the near future.
Insights
Pseudomonas aeruginosa infections are a growing challenge in intensive care units due to antimicrobial resistance. Developing effective vaccines is crucial for preventing these difficult-to-treat nosocomial infections.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Critical Care Medicine
Background:
- Pseudomonas aeruginosa is a frequent cause of hospital-acquired infections in intensive care units (ICUs).
- Antimicrobial resistance in P. aeruginosa complicates treatment and is associated with poorer patient outcomes.
- Effective prevention strategies are urgently needed.
Purpose of the Study:
- To highlight the significance of Pseudomonas aeruginosa infections in ICUs.
- To emphasize the growing challenge posed by antimicrobial resistance.
- To underscore the importance of developing novel prevention methods, particularly vaccines.
Main Methods:
- Review of current literature on Pseudomonas aeruginosa infections in ICU settings.
- Analysis of trends in antimicrobial resistance.
- Identification of promising vaccine candidates and targets.
Main Results:
- P. aeruginosa infections are linked to worse outcomes in ICU patients.
- Increasing antimicrobial resistance presents a significant therapeutic challenge.
- Several vaccine candidates are in clinical evaluation, with ongoing discovery of new targets.
Conclusions:
- Vaccine development is a critical area of research for combating P. aeruginosa infections.
- Continued investigation into novel vaccine targets and agents is necessary.
- Preventive strategies are essential to mitigate the impact of these infections in ICUs.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:29Pneumonia I: Introduction